TGF-β / Smad Signaling(TGF-β / Smad 信号转导)
Transforming growth factor-beta (TGF-beta) is a multifunctional cytokine that regulates proliferation, migration, differentiation, and survival of many different cell types. Deletion or mutation of different members of the TGF-β family have been shown to cause vascular remodeling defect and absence of mural cell formation, leading to embryonic lethality or severe vascular disorders. TGF-β induces smooth muscle differentiation via Notch or SMAD2 and SMAD3 signaling in ES cells or in a neural crest stem cell line. TGF-β binds to TGF-βRI and to induce phosphorylation of SMAD2/3, thereby inhibiting proliferation, tube formation, and migration of endothelial cells (ECs).
TGF-β is a pluripotent cytokine with dual tumour-suppressive and tumour-promoting effects. TGF-β induces the epithelial-to-mesenchymal transition (EMT) leading to increased cell plasticity at the onset of cancer cell invasion and metastasis.
Products for TGF-β / Smad Signaling
- Cat.No. 产品名称 Information
-
GC17767
Dihydrosphingosine
二氢(神经)鞘氨醇
A mixture of sphingolipid pathway intermediates -
GC34060
Disitertide (P144)
地司特泰,P144
Disitertide (P144)是转化生长因子β1(TGF-β1)受体I型的特异性抑制剂。 -
GC68333
Disitertide diammonium
P144 diammonium
Disitertide (P144)是转化生长因子β1(TGF-β1)受体I型的特异性抑制剂。 -
GC60782
Disitertide TFA
P144 TFA
Disitertide (P144)是转化生长因子β1(TGF-β1)受体I型的特异性抑制剂。 -
GC72959
DJ4
DJ4是ROCK1/2(IC50值:5和50 nM)和MRCKα/β(IC50值为10和100 nM)的ATP竞争性抑制剂。
-
GC14298
DMH-1
BMP Inhibitor II, DorsoMorphin Homolog 1, VU036482
A potent ALK2 inhibitor -
GC17243
Dorsomorphin (Compound C)
6-[4-[2-(1-哌啶基)乙氧基]苯基]-3-(4-吡啶基)吡唑并[1,5-A]嘧啶,Compound C
Dorsomorphin(Compound C)是一种细胞渗透的AMPK抑制剂。 -
GC12560
Dorsomorphin (Compound C) 2HCl
BML-275 2HCl,Compound C 2HCl
IC50:Dorsomorphin 以剂量依赖性方式抑制 BMP4 诱导的 BMP 反应性 SMAD 磷酸化(半数最大抑制浓度 (IC50) =0.47 mM)。
-
GC35897
DPH
5-(3-(4-氟苯基)-1-苯基-1H-吡唑-4-基)咪唑烷-2,4-二酮
DPH 是一种有效的细胞渗透性 c-Abl 激活剂,在刺激 c-Abl 活化方面表现出有效的酶和细胞活性。 -
GC73653
DT-6
DT-6是一种有效的TGF-β1抑制剂。
-
GC90543
EGFR Peptide (human, mouse) (myristoylated) (trifluoroacetate salt)
Epidermal Growth Factor Receptor Peptide, Myr-Arg-Lys-Arg-Thr-Leu-Arg-Arg-Leu-OH, N-myristoyl-RKRTLRRL
一种PKC抑制剂
-
GC69052
Elezanumab
依来努单抗; ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)
Elezanumab (ABT-555; AE12-1Y-QL) 是一种人单克隆抗体,可选择性靶向排斥性引导分子 A (RGMa)。Elezanumab 通过 SMAD1/5/8 通路有效抑制 RGMa 介导的 BMP 信号传导,IC50 约为 97 pM。Elezanumab 促进神经元损伤和脱髓鞘模型中的神经再生和神经保护作用,可结合 N 末端 RGMa、阻断 BMP 信号传导并缺乏 RGMc 交叉反应性。Elezanumab 具有神经再生和神经保护活性,对铁代谢没有影响。 -
GC32914
EMT inhibitor-1
EMTinhibitor-1是Hippo,TGF-β和Wnt信号通路的抑制剂,并拥有抗肿瘤活性。
-
GC11499
Enzastaurin (LY317615)
恩扎妥林; LY317615
An inhibitor of PKC and Akt signaling -
GC65329
EW-7195
EW-7195 是一种有效的、选择性 ALK5 (TGFβR1) 抑制剂,IC50 为 4.83 nM。EW-7195 对 ALK5 的选择性是 p38α 的 300 多倍。EW-7195 能有效抑制 TGF-β1 诱导的 Smad 信号转导、上皮间质转化 (EMT) 和乳腺癌向肺转移。
-
GC13354
EW-7197
Vactosertib,TEW-7197
EW-7197是一种口服有效的丝氨酸/苏氨酸激酶抑制剂,靶向转化生长因子(TGF)-β受体I(TGFBR1),也称为激活素受体样激酶5(ALK5),其IC50值为12.9nM。 -
GC13869
Fasudil
法舒地尔; HA-1077; AT877
Fasudil(法舒地尔;HA-1077;AT877)是一种非特异性RhoA/ROCK抑制剂,对ROCK1的Ki为0.33μM,IC50为0.158μM,对ROCK2和PKA、PKC、PKG的IC50分别为4.58μM、12.30μM、1.650μM。 -
GC14289
Fasudil (HA-1077) HCl
盐酸法舒地尔; HA-1077 Hydrochloride; AT-877 Hydrochloride
Fasudil(法舒地尔;HA-1077;AT877)是一种非特异性RhoA/ROCK抑制剂,对ROCK1的Ki为0.33μM,IC50为0.158μM,对ROCK2和PKA、PKC、PKG的IC50分别为4.58μM、12.30μM、1.650μM。 -
GC32867
Flumatinib (HHGV678)
4-[(4-甲基-1-哌嗪基)甲基]-N-[6-甲基-5-[[4-(3-吡啶基)-2-嘧啶基]氨基]-3-吡啶基]-3-(三氟甲基)苯甲酰胺,HHGV678
A Bcr-Abl inhibitor -
GC13914
Flumatinib mesylate
甲磺酸氟马替尼; HHGV678 mesylate
A Bcr-Abl inhibitor -
GC12027
FR 236924
FR236924
An activator of PKCε -
GC65539
Fresolimumab
非苏木单抗,GC1008
Fresolimumab是一种高亲和力的人源化单克隆抗体,能够结合并抑制蛋白转化生长因子β(TGFβ)的所有亚型。Fresolimumab对TGFβ1、TGFβ2和TGFβ3的Kd值分别为1.7±0.6nM、3.0±1.2nM、2.0±1.2nM。
-
GC15431
GF 109203X (Bisindolylmaleimide I)
Gö 6850;Bisindolylmaleimide I
GF 109203X是蛋白激酶C的选择性抑制剂,对蛋白激酶C的α和β1亚型具有选择性,对α、β1、δ、ε和ζ亚型的IC50值分别为0.0084、0.0180、0.210、0.132和5.8μM。GF 109203X可选择性抑制MLCK、PKG、PKA (IC50分别为0.6, 4.6, and 33μM)。 -
GC36167
GMB-475
GMB-475 is a proteolysis-targeting chimera (PROTAC) that allosterically targets BCR-ABL1 protein and recruit the E3 ligase Von Hippel-Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.
-
GC10858
GNF 2
3-[6-[[4-(三氟甲氧基)苯基]氨基]-4-嘧啶基]苯甲酰胺
An allosteric inhibitor of Bcr-Abl -
GC15079
GNF 5
An allosteric inhibitor of Bcr-Abl
-
GC10607
GNF-7
A multi-kinase inhibitor
-
GC15564
Go 6976
5,6,7,13-四氢-13-甲基-5-氧代-12H-吲哚并[2,3-A]吡咯并[3,4-C]咔唑-12-丙腈,Go6976;Go-6976
A PKCα/β1 inhibitor -
GC16907
Go 6983
3-[1-[3-(二甲基氨基)丙基]-5-甲氧基-1H-吲哚-3-基]-4-(1H-吲哚-3-基)-1H-吡咯-2,5-二酮,Goe 6983;Go6983;Go-6983
Go 6983 (GÖ 6983) 是 PKC 抑制剂化合物的双吲哚基马来酰亚胺组之一,Go 6983 (GÖ 6983) 能够区分 PKC mu 和其他 PKC 同工酶。 -
GC38791
GSK-25
GSK-25 是一种有效的、选择性的,具有口服活性的 ROCK1 抑制剂 (IC50=7 nM)。GSK-25 对 31 种激酶以及 RSK1 和 p70S6K 保持良好的选择性 (RSK1: IC50=398 nM, p70S6K: IC50=1 μM)。GSK-25 可抑制 P450 (CYP2C9、CYP2D6、CYP3A4的IC50 分别为2.5、5.2、2.5 μM)。
-
GC19177
GSK180736A
A ROCK1 and GRK2 inhibitor
-
GC17936
GSK269962A
N-[3-[[2-(4-氨基呋咱-3-基)-1-乙基-1H-咪唑并[4,5-C]吡啶-6-基]氧]苯基]-4-[[2-(4-吗啉基)乙基]氧]苯甲酰胺,GSK 269962
A ROCK1 and ROCK2 inhibitor -
GC25482
GSK269962A HCl
GSK269962B, GSK269962, GSK 269962
GSK269962A HCl (GSK269962B, GSK269962) is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively. -
GC18119
GSK429286A
N-(6-氟-1H-吲唑-5-基)-2-甲基-6-氧代-4-[4-(三氟甲基)苯基]-1,4,5,6-四氢-3-吡啶甲酰胺
A ROCK inhibitor -
GC11878
GW788388
An inhibitor of ALK5 (TGFBR1)
-
GC10915
GZD824
GZD824 dimesylate; HQP1351 dimesylate
A Bcr/Abl inhibitor -
GC33201
GZD856
GZD856是一种新型,有口服活性的PDGFRα/β抑制剂,IC50分别为68.6和136.6nM。具有抗肺癌活性。也是Bcr-AblT315I的抑制剂,对Bcr-Abl和T315I突变型的IC50分别为19.9和15.4 nM。
-
GC62453
GZD856 formic
GZD856 formic 是一种有效的和具有口服活性的 PDGFRα/β 抑制剂,IC50 值分别为 68.6 和 136.6 nM。GZD856 formic 也是 Bcr-AblT315I 的抑制剂,对天然 Bcr-Abl 和 T315I 突变型的 IC50 值分别为 19.9 和 15.4 nM。GZD856 formic 具有抗肿瘤活性。
-
GC36207
H-1152
A ROCK inhibitor
-
GC36208
H-1152 dihydrochloride
H-1152 dihydrochloride (2HCl) is a membrane-permeable and selective inhibitor of Rho-associated protein kinase (ROCK). H-1152 inhibits ROCK2, PKA, PKC, PKG, AuroraA and CaMK2 with IC50 of 0.0120 μM, 3.03 μM, 5.68 μM, 0.360 μM, 0.745 μM and 0.180 μM, respectively.
-
GC31650
Halofuginone (RU-19110)
常山酮; RU-19110
Halofuginone (RU-19110) is the competitively inhibitor of prolyl-tRNA synthetase with Ki of 18.3 nM.It could also down-regulate Smad3 and blocked TGF-β signaling at 10 ng/ml in mammal. -
GC31950
Halofuginone hydrobromide (RU-19110 (hydrobromide))
常山酮溴酸盐; RU-19110 hydrobromide
Halofuginone (RU-19110) hydrobromid 是一种Ferifugine 衍生物,是一种竞争性脯氨酰-tRNA 合成酶抑制剂,Ki 为 18.3 nM。 -
GC10299
Hexadecyl Methyl Glycerol
1-O-hexadecyl-2-O-methyl-sn-Glycerol
A synthetic DAG -
GC71477
HG-7-86-01
HG-7-86-01(化合物26)是II型酪氨酸激酶抑制剂。
-
GC15018
Hispidin
6-[(1E)-2-(3,4-二羟基苯基)乙烯基]-4-羟基-2H-吡喃-2-酮
A polyphenol with diverse biological activities -
GC64326
Hydrochlorothiazid-d2
氢氯噻嗪-D2,HCTZ-d2
Hydrochlorothiazid-d2 (HCTZ-d2) 是 Hydrochlorothiazide 的氘代物。Hydrochlorothiazide (HCTZ) 是一种口服有效的噻嗪类的利尿药,可抑制转化 TGF-β/Smad 信号通路。Hydrochlorothiazide 通过打开钙激活钾 (KCA) 通道具有直接的血管松弛作用。Hydrochlorothiazide 改善心脏功能,减少纤维化并具有降压作用。 -
GC17523
Hydrochlorothiazide
氢氯噻嗪; HCTZ
A thiazide diuretic -
GC74190
Hydrochlorothiazide-13C6
HCTZ-13C6
Hydrochlorothiazide-13C6是13C标记的屈氯噻嗪。 -
GC10901
Hydroxyfasudil
羟基法舒地尔; HA-1100
Hydroxyfasudil 是一种 ROCK 抑制剂,对 ROCK1 和 ROCK2 的 IC50 分别为 0.73 和 0.72 μM。 -
GC10338
Hydroxyfasudil hydrochloride
羟基法舒地尔盐酸盐; HA-1100 hydrochloride; HA 1100 hydrochloride; HA1100 hydrochloride
A ROCK inhibitor